Abstract��OBJECTIVE To evaluate the efficacy and safety of rivaroxaban in the treatment of deep venous thrombosis(DVT). METHODS PubMed, Embase, Cochrane Library, Web of Science, Clinical Trials, CNKI, CBM and WANFANG database were systematically searched. All databases had been searched from up to August 2016. All randomized controlled trials (RCTs) of rivaroxaban therapy in patients with deep venous thrombosis were selected. Meta-analysis was carried out by using RevMan 5.3 software. The incidence of recurrent DVT, recurrent VTE, DVT, pulmonary embolism(PE), major bleeding, clinical relevant non-major bleeding(CRNMB) and all-cause mortality after the treatment were compared and the results were presented with risk ratio (RR) with 95% confidence interval (CI). RESULTS Total 5 RCTs of 4 737 cases were included in this study, including 1 605 cases accepted rivaroxaban (treatment group), other of 3 132 cases accepted other drugs (control group). The results of Meta-analysis were as follows the incidence of recurrent DVT in the rivaroxaban group was lower than that in the unfractionated heparin/low molecular heparin+ vitamin K antagonists (UFH/LMWH+VKA) group (P=0.002). There was no significant difference in the incidence of pulmonary embolism, venous thromboembolism, major bleeding, CRNMB and all-cause mortality between the treatment and control group (P��0.05). CONCLUSION In the treatment of DVT, rivaroxban shows better efficacy than that of traditional anticoagulant therapy (UFH/LMWH+VKA) and it will not increase the risk of adverse events such as bleeding and death.
��ϼ, �����, ������. ����ɳ���������Ѫ˨��Ч�ԺͰ�ȫ�Ե�Meta����[J]. �й�ҩѧ��־, 2017, 52(21): 1948-1952.
YANG Xia, DONG Shu-jie, ZHAI Suo-di. Meta-analysis of Efficacy and Safety of Rivaroxaban for Treatment of Deep Venous Thrombosis. Chinese Pharmaceutical Journal, 2017, 52(21): 1948-1952.
Department of vascular surgery, Surgery branch of Chinese medical assiociation, guidelines for diagnosis and treatment of deep venous thrombosis (The 2th Edition)[J]. Chin J Vasc Surg(�л������־), 2012, 50(7):611-614.
[2]
Cardiology Branch of Chinese Medical Association. Chinese expert consensus warfarin therapy [J]. Chin J Intern Med(�л��ڿ���־), 2013, 52(1):76-82.
[3]
XIN S J, LI X. Classification and rational application of anticoagulant drugs [J]. Chin J Practical Surgery(�й�ʵ�������־), 2011(12):1138-1140.
[4]
SAMAMA M M. The mechanism of action of rivaroxaban-an oral, direct Factor Xa inhibitor-compared with other anticoagulants[J]. Thromb Res, 2011, 127(6):497-504.
[5]
PERABORN E, STRASSBURGER J, WILMEN A, et al. In vitro and in vivo studies of the novel antithrombotic agent BAY 59-7939--an oral, direct Factor Xa inhibitor[J]. Thromb Haemost, 2005, 3(3):514-21.
[6]
National Institute for Health and Clinical Excellence. Rivaroxaban for the treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism. Technology appraisal 261.2012. http://www.nice.org.uk/ta261(26 January 2015, date last accessed).
[7]
CASTELLUCCI L A, CAMERON C, LE G G, et al. Clinical and safety outcomes associated with treatment of acute venous thromboembolism: a systematic review and Meta-analysis[J]. Jama, 2014, 312(11):1122.
[8]
GOMEZ-OUTES A, TERLEIRA-FERNANDEZ A I, LECUMBERRI R, et al. Direct oral anticoagulants in the treatment of acute venous thromboembolism: a systematic review and Meta-analysis[J]. Thromb Res, 2014, 134(4):774-782.
[9]
LANDMAN G W, GANS R O. Oral rivaroxaban for symptomatic venous thromboembolism[J]. N Engl J Med, 2010, 363(26):2499-2510.
[10]
AGNELLI G, GALLUS A, GOLDHABER S Z, et al. Treatment of proximal deep-vein thrombosis with the oral direct factor Xa inhibitor rivaroxaban (BAY 59-7939): the ODIXa-DVT(oral direct factor Xa inhibitor BAY 59-7939 in patients with acute symptomatic deep-vein thrombosis) study[J]. J Vasc Surg, 2007, 47(3):180-187.
[11]
BULLER H R, LENSING A W, PRINS M H, et al. A dose-ranging study evaluating once-daily oral administration of the factor Xa inhibitor rivaroxaban in the treatment of patients with acute symptomatic deep vein thrombosis: the Einstein-DVT Dose-Ranging Study[J]. Blood, 2008, 112(6):2242-2247.
[12]
YAMADA N. Oral rivaroxaban for Japanese patients with symptomatic venous thromboembolism-the J-EINSTEIN DVT and PE program[J]. Thromb J, 2015, 13(1):1-8.
[13]
XU K.The efficacy and safety of rivaroxaban in the prevention and treatment for thrombo-embolic diseases in the very old patients [D]. Beijing:The General Hospital of the People��s Liberation Army, 2014.
[14]
SHANNON M B, JEFFREY S G. Treatment of deep venous thrombosis[J]. J China Prescription Drug(�й�����ҩ), 2004(10):31-35.
[15]
HUANG L, LIU F, LI Y Z. Pharmacological effects and clinical application of a new oral Xa factor inhibitor-rivaroxaban [J]. Chin Pharm J(�й�ҩѧ��־), 2010, 45(21):1682-1684.
[16]
KEARON C, AKL E A, ORNELAS J, et al. Antithrombotic therapy for VTE disease: CHEST Guideline and Expert Panel Report[J]. Chest, 2016, 149(2):315-352.
2017, Vol. 52 
